COVID-19 Will Spur Decentralized and Hybrid Trials – Novartis Hails Digital Investment

Decentralized Trials Can Only Soften The Blow

 
• By Andrew McConaghie

The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.

Novartis_Building
Novartis says its investment in digitizing clinical trial monitoring has helped during the crisis

More from COVID-19

More from Scrip